Soluble plasma-derived von Willebrand factor assembles to a haemostatically active filamentous network

Summary

The large glycoprotein vonWillebrand factor (VWF) is involved in the initial haemostatic reaction mediating the interaction between platelets and the injured vessel wall. It has been demonstrated that unusually large VWF (ULVWF) multimers after being released from endothelium are capable of developing elongated membrane-anchored strings that are hyperactive to bind platelets. In the present study we investigated whether soluble plasma-derived VWF is competent to develop similar thrombotically active multimers. We demonstrated that soluble VWF multimers isolated from human plasma self-assemble to a network of fibers immobilized on a collagen matrix and are functionally active to bind platelets. Formation of these VWF fibers depends on shear flow, concentration of solubleVWF, and a suitable binding surface. Self-assembly of soluble VWF does not require the presence of cellular membrane ligands. The network of fibers is subjected to rapid degradation by proteolytic activity of plasma ADAMTS-13.Atomic force microscopy images elucidate the nanostructure of VWF fibers and illustrate self-association and -aggregation of several filamentous multimers. Together, these results suggest that circulatingVWF can contribute to a formation of hyperactive VWF fibers on exposed subendothelial collagen during vascular injury.

Keywords

ULVWF multimers - platelet adhesion - atomic force microscopy - soluble VWF

• References

• 1 Wagner DD. New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321-1324.
• 2 Blann AD. Plasma von Willebrand factor, thrombosis, and the endothelium: The first 30 years. Thromb Haemost 2006; 95: 49-55.
• 3 de Groot PG, Ottenhof-Rovers M, van Mourik JA. et al. Evidence that the primary binding site of von Willebrand factor that mediates platelet adhesion on subendothelium is not collagen. J Clin Invest 1988; 82: 65-73.
• 4 Ruggeri ZM. Von Willebrand factor, platelets and endothelial cell interactions. J Thromb Haemost 2003; 1: 1335-1342.
• 5 Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67: 395-424.
• 6 Dong JF, Moake JL, Nolasco LH. et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002; 100: 4033-4039.
• 7 Sporn LA, Marder VJ, Wagner DD. Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 1986; 18: 185-190.
• 8 Hannah MJ, Williams R, Kaur J. et al. Biogenesis of Weibel-Palade bodies. Semin Cell Develop Biol 2002; 13: 313-324.
• 9 Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95: 355-360.
• 10 Michaux G, Abbitt KB, Collinson LM. et al. The physiological function of von Willebrand's factor dep- ends on its tubular storage in endothelial Weibel-Palade bodies. Dev Cell 2006; 10: 223-232.
• 11 Vischer UM, Barth H, Wollheim CB. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 883-891.
• 12 Goerge T, Niemeyer A, Rogge P. et al. Secretion pores in human endothelial cells during acute hypoxia. J Membrane Biol 2002; 187: 203-211.
• 13 Padilla A, Moake JL, Bernardo A. et al. P-selectin anchors newly released ultralarge von Willebrand factor multimers to the endothelial cell surface. Blood 2004; 103: 2150-2156.
• 14 Moake JL. Mechanisms of disease: thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
• 15 Lammle B, Hovinga JAK, Alberio L. Thrombotic thrombocytopenic purpura. J Thromb Haemost 2005; 3: 1663-1675.
• 16 Cines DB, Konkle BA, Furlan M. Thrombotic thrombocytopenic purpura: a paradigm shift?. Thromb Haemost 2000; 84: 528-535.
• 17 Levy GG, Nichols WC, Lian EC. et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488-494.
• 18 Furlan M, Robles R, Lammle B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996; 87: 4223-4234.
• 19 Furlan M. Von Willebrand factor: molecular size and functional activity. Ann Hematol 1996; 72: 341-348.
• 20 Xie L, Chesterman CN, Hogg PJ. Reduction of von Willebrand factor by endothelial cells. Thromb Haemost 2000; 84: 506-513.
• 21 Stock C, Gassner B, Hauck CR. et al. Migration of human melanoma cells depends on extracellular pH and Na+ /H+ exchange. J Physiol 2005; 567: 225-238.
• 22 Sakakibara M, Goto S, Eto K. et al. Application of ex vivo flow chamber system for assessment of stent thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 1360-1364.
• 23 Bernardo A, Ball C, Nolasco LH. et al. Platelets adhered to endothelial cell-bound ultra-large von Willebrand factor strings support leukocyte tethering and rolling under high shear stress. J Thromb Haemost 2005; 3: 562-570.
• 24 Siedlecki CA, Lestini BJ, Kottke-Marchant K. et al. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 1996; 88: 2939-2950.
• 25 Novak L, Deckmyn H, Damjanovic S. et al. Shear-dependent morphology of von Willebrand factor bound to immobilized collagen. Blood 2002; 99: 2070-2076.
• 26 Hathcock JJ. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol 2006; 26: 1729-1737.
• 27 Tangelder GJ, Slaaf DW, Arts T. et al. Wall shear rate in arterioles in vivo: least estimates from platelet velocity profiles. Am J Physiol 1988; 254: H1059-H1064.
• 28 Sethuraman A, Han M, Kane RS. et al. Effect of surface wettability on the adhesion of proteins. Langmuir 2004; 20: 7779-7788.
• 29 Lyubchenko YL, Jacobs BL, Lindsay SM. Atomic force microscopy of reovirus dsRNA: a routine tech- nique for length measurements. Nucleic Acids Res 1992; 20: 3983-3986.
• 30 Schneider SW, Lärmer J, Henderson RM. et al. Molecular weights of individual proteins correlate with molecular volumes measured by atomic force microscopy. Pflügers Arch – Eur J Physiol 1998; 435: 362-367.
• 31 Schneider SW, Sritharan KC, Geibel JP. et al. Surface dynamics in living acinar cells imaged by atomic force microscopy: identification of plasma membrane structures involved in exocytosis. Proc Natl Acad Sci USA 1997; 94: 316-321.
• 32 Kostousov V, Fehr J, Bombeli T. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS-13. Thromb Res 2006; 118: 723-731.
• 33 Gerritsen HE, Turecek PL, Schwarz HP. et al. Assay of von Willebrand factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF. A tool for the diagnosis of thrombotic thrombocytopenic purpura (TTP). Thromb Haemost 1999; 82: 1386-1389.
• 34 Savage B, Sixma JJ, Ruggeri ZM. Functional self-association of von Willebrand factor during platelet adhesion under flow. Proc Natl Acad Sci USA 2002; 99: 425-430.
• 35 Chow TW, Hellums JD, Moake JL. et al. Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 1992; 80: 113-120.
• 36 Dopheide SM, Maxwell MJ, Jackson SP. Shear-dependent tether formation during platelet translocation on von Willebrand factor. Blood 2002; 99: 159-167.
• 37 Liu L, Choi H, Bernardo A. et al. Platelet-derived vWF-cleaving metalloprotease ADAMTS-13. J Thromb Haemost 2005; 3: 2536-2544.
• 38 Fowler WE, Fretto LJ, Hamilton KK. et al. Substructure of human von Willebrand factor. J Clin Invest 1985; 76: 1491-1500.
• 39 Raghavachari M, Tsai H, Kottke-Marchant K. et al. Surface dependent structures of von Willebrand factor observed by AFM under aqueous conditions. Colloids Surf B Biointerfaces 2000; 19: 315-324.
• 40 Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 1979; 279: 636-638.
• 41 Mannucci PM, Karimi M, Mosalaei A. et al. Patients with localized and disseminated tumors have reduced but measurable levels of ADAMTS-13 (von Willebrand factor cleaving protease). Haematologica 2003; 88: 454-458.
• 42 Ulrichts H, Vanhoorelbeke K, Girma JP. et al. The von Willebrand factor self-association is modulated by a multiple domain interaction. J Thromb Haemost 2005; 3: 552-561.
• 43 Xie L, Chesterman CN, Hogg PJ. Control of von Willebrand factor multimer size by thrombospondin-1. J Exp Med 2004; 193: 1341-1349.
• 44 Ganderton T, Berndt MC, Chesterman CN. et al. Hypothesis for control of von Willebrand factor multimer size by intra-molecular thiol-disulphide exchange. J Thromb Haemost 2007; 5: 204-206.
• 45 Andre P, Denis CV, Ware J. et al. Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood 2000; 96: 3322-3328.
• 46 Motto DG, Chauhan AK, Zhu G. et al. Shigatoxin triggers thrombotic thrombocytopenic purpura in genetically susceptible ADAMTS13-deficient mice. J Clin Invest 2005; 115: 2752-2761.
• 47 Chauhan AK, Motto DG, Lamb CB. et al. Systemic antithrombotic effects of ADAMTS13. J Exp Med 2006; 203: 767-776.
• 48 Bernardo A, Ball C, Nolasco LH. et al. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow. Blood 2004; 104: 100-106.
• 49 Nolasco LH, Turner NA, Bernardo A. et al. Hemolytic uremic syndrome-associated shiga toxins promote endothelial cell secretion and impair ADAMTS-13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106: 4199-4209.